Literature DB >> 33654941

Mitochondrial Respiratory Measurements in Patient-derived Fibroblasts.

Prashant Mishra1, Ting Zhang2, Ming Guo2,3,4, David Chan1.   

Abstract

Mitochondrial dysfunction is associated with a number of human diseases. As an example, we recently established in vivo Drosophila models of IBMPFD (Inclusion body myopathy, Paget disease, and frontotemporal dementia), and uncovered that human disease mutations of the p97/VCP (Valosin Containing Protein) gene behave as hyperactive alleles associated with mitochondrial defects. Pharmacologic inhibition of VCP strongly suppressed disease and mitochondrial pathology in these animal models. In this protocol, we describe a method to evaluate mitochondrial respiratory function in IBMPFD patient-derived fibroblasts, as well as investigate the role of pharmacologic treatments. These experiments complement work done in animal models by investigating mitochondrial biology and the pharmacologic response in a human cell-based model of the disease. In principle, this technique can be used to investigate mitochondrial respiratory function for any disease in which patient-derived fibroblasts are available.
Copyright © 2019 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Inclusion body myopathy; Mitochondrial respiration; Paget disease and frontotemporal dementia (IBMPFD); Patient-derived fibroblasts; Seahorse XF assay; VCP/p97

Year:  2019        PMID: 33654941      PMCID: PMC7853990          DOI: 10.21769/BioProtoc.3446

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  7 in total

1.  Hereditary spastic paraplegia caused by a mutation in the VCP gene.

Authors:  Susanne T de Bot; Helenius J Schelhaas; Erik-Jan Kamsteeg; Bart P C van de Warrenburg
Journal:  Brain       Date:  2012-09-18       Impact factor: 13.501

2.  A novel mutation in VCP causes Charcot-Marie-Tooth Type 2 disease.

Authors:  Michael A Gonzalez; Shawna M Feely; Fiorella Speziani; Alleene V Strickland; Matt Danzi; Chelsea Bacon; Youjin Lee; Tsui-Fen Chou; Susan H Blanton; Conrad C Weihl; Stephan Zuchner; Michael E Shy
Journal:  Brain       Date:  2014-08-14       Impact factor: 13.501

Review 3.  Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system.

Authors:  Hemmo Meyer; Monika Bug; Sebastian Bremer
Journal:  Nat Cell Biol       Date:  2012-02-02       Impact factor: 28.824

4.  Sulforhodamine B colorimetric assay for cytotoxicity screening.

Authors:  Vanicha Vichai; Kanyawim Kirtikara
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

5.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein.

Authors:  Giles D J Watts; Jill Wymer; Margaret J Kovach; Sarju G Mehta; Steven Mumm; Daniel Darvish; Alan Pestronk; Michael P Whyte; Virginia E Kimonis
Journal:  Nat Genet       Date:  2004-03-21       Impact factor: 38.330

6.  Valosin-containing protein (VCP) mutations in sporadic amyotrophic lateral sclerosis.

Authors:  Yevgeniya Abramzon; Janel O Johnson; Sonja W Scholz; J P Taylor; Maura Brunetti; Andrea Calvo; Jessica Mandrioli; Michael Benatar; Gabriele Mora; Gabriella Restagno; Adriano Chiò; Bryan J Traynor
Journal:  Neurobiol Aging       Date:  2012-05-08       Impact factor: 4.673

7.  Valosin-containing protein (VCP/p97) inhibitors relieve Mitofusin-dependent mitochondrial defects due to VCP disease mutants.

Authors:  Ting Zhang; Prashant Mishra; Bruce A Hay; David Chan; Ming Guo
Journal:  Elife       Date:  2017-03-21       Impact factor: 8.140

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.